These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 31809217)

  • 1. A systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States.
    Lister JJ; Weaver A; Ellis JD; Himle JA; Ledgerwood DM
    Am J Drug Alcohol Abuse; 2020 May; 46(3):273-288. PubMed ID: 31809217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is telemedicine the answer to rural expansion of medication treatment for opioid use disorder? Early experiences in the feasibility study phase of a National Drug Abuse Treatment Clinical Trials Network Trial.
    Hser YI; Ober AJ; Dopp AR; Lin C; Osterhage KP; Clingan SE; Mooney LJ; Curtis ME; Marsch LA; McLeman B; Hichborn E; Lester LS; Baldwin LM; Liu Y; Jacobs P; Saxon AJ
    Addict Sci Clin Pract; 2021 Apr; 16(1):24. PubMed ID: 33879260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming Barriers to Prescribing Buprenorphine for the Treatment of Opioid Use Disorder: Recommendations from Rural Physicians.
    Andrilla CHA; Moore TE; Patterson DG
    J Rural Health; 2019 Jan; 35(1):113-121. PubMed ID: 30339720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio.
    Molfenter T; Sherbeck C; Zehner M; Quanbeck A; McCarty D; Kim JS; Starr S
    Subst Abuse Treat Prev Policy; 2015 Mar; 10():13. PubMed ID: 25884206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addressing opioid use disorder among rural pregnant and postpartum women: a study protocol.
    Bryan MA; Smid MC; Cheng M; Fortenberry KT; Kenney A; Muniyappa B; Pendergrass D; Gordon AJ; Cochran G
    Addict Sci Clin Pract; 2020 Oct; 15(1):33. PubMed ID: 33129355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. U.S. trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018.
    Ghertner R
    Drug Alcohol Depend; 2019 Nov; 204():107527. PubMed ID: 31525570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementing Treatment of Opioid-Use Disorder in Rural Settings: a Focus on HIV and Hepatitis C Prevention and Treatment.
    Havens JR; Walsh SL; Korthuis PT; Fiellin DA
    Curr HIV/AIDS Rep; 2018 Aug; 15(4):315-323. PubMed ID: 29948609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rural access to MAT in Pennsylvania (RAMP): a hybrid implementation study protocol for medication assisted treatment adoption among rural primary care providers.
    Cochran G; Cole ES; Warwick J; Donohue JM; Gordon AJ; Gellad WF; Bear T; Kelley D; DiDomenico E; Pringle J
    Addict Sci Clin Pract; 2019 Aug; 14(1):25. PubMed ID: 31366408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence.
    Godersky ME; Saxon AJ; Merrill JO; Samet JH; Simoni JM; Tsui JI
    Addict Sci Clin Pract; 2019 Mar; 14(1):11. PubMed ID: 30867068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine prescribing practice trends and attitudes among New York providers.
    Kermack A; Flannery M; Tofighi B; McNeely J; Lee JD
    J Subst Abuse Treat; 2017 Mar; 74():1-6. PubMed ID: 28132694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barriers to accessing opioid agonist therapy in pregnancy.
    Bedrick BS; O'Donnell C; Marx CM; Friedman H; Carter EB; Stout MJ; Kelly JC
    Am J Obstet Gynecol MFM; 2020 Nov; 2(4):100225. PubMed ID: 33345932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experiences of three states implementing the Medicaid health home model to address opioid use disorder-Case studies in Maryland, Rhode Island, and Vermont.
    Clemans-Cope L; Wishner JB; Allen EH; Lallemand N; Epstein M; Spillman BC
    J Subst Abuse Treat; 2017 Dec; 83():27-35. PubMed ID: 29129193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. U.S. Healthcare Workers' Perspective of Outpatient Provision of Methadone: A Scoping Review.
    Hernandez SE; Gilson AM; Ku TL; Gassman M; Ford JH
    Subst Use Addctn J; 2024 Oct; 45(4):753-764. PubMed ID: 39068538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Barriers to Integrated Medication-Assisted Treatment for Rural Patients With Co-occurring Disorders: The Gap in Managing Addiction.
    Snell-Rood C; Pollini RA; Willging C
    Psychiatr Serv; 2021 Aug; 72(8):935-942. PubMed ID: 33530734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disparities in Access to Opioid Treatment Programs and Office-Based Buprenorphine Treatment Across the Rural-Urban and Area Deprivation Continua: A US Nationwide Small Area Analysis.
    Amiri S; McDonell MG; Denney JT; Buchwald D; Amram O
    Value Health; 2021 Feb; 24(2):188-195. PubMed ID: 33518025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Primary Care in Improving Access to Medication-Assisted Treatment for Rural Medicaid Enrollees with Opioid Use Disorder.
    Cole ES; DiDomenico E; Cochran G; Gordon AJ; Gellad WF; Pringle J; Warwick J; Chang CH; Kim JY; Kmiec J; Kelley D; Donohue JM
    J Gen Intern Med; 2019 Jun; 34(6):936-943. PubMed ID: 30887440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rural-urban disparities in the availability of hospital-based screening, medications for opioid use disorder, and addiction consult services.
    Franz B; Cronin CE; Lindenfeld Z; Pagan JA; Lai AY; Krawczyk N; Rivera BD; Chang JE
    J Subst Use Addict Treat; 2024 May; 160():209280. PubMed ID: 38142042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barriers and perceived usefulness of an ECHO intervention for office-based buprenorphine treatment for opioid use disorder in North Carolina: A qualitative study.
    Shea CM; Gertner AK; Green SL
    Subst Abus; 2021; 42(1):54-64. PubMed ID: 31809679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update.
    Andrilla CHA; Moore TE; Patterson DG; Larson EH
    J Rural Health; 2019 Jan; 35(1):108-112. PubMed ID: 29923637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidimensional assessment of access to medications for opioid use disorder across urban and rural communities: A scoping review.
    Bommersbach T; Justen M; Bunting AM; Funaro MC; Winstanley EL; Joudrey PJ
    Int J Drug Policy; 2023 Feb; 112():103931. PubMed ID: 36563489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.